July 20, 2015 – Early nutrition and adiposity have been linked to atopic dermatitis (AD) development.
July 20, 2015 – Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug.
July 13, 2015 – Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis.
July 10, 0215 – Eczema can be challenging any time of year. Here are some tips for managing eczema during the summer from people just like you, friends on NEA’s Facebook page.
June 16,2015 – Dermatologists have long known that available treatments for chronic itch, including eczema, are simply not up to scratch. But scientists have now discovered a new gene that promotes itch, suggesting a way forward for powerful new therapies.
June 8, 2015 – I have been a part of the eczema community, and the NEA Board of Directors, for many years I never thought I would see the day when hope and opportunity would converge and we would see a promising future for eczema on the horizon. That day is now!
June 1, 2015 – Patients with either vitiligo, especially early-onset disease, or AA, especially alopecia totalis or alopecia universalis, have significantly increased risk for AD.
May 29, 2015 – Linalyl acetate, a fragrance chemical that is one of the main constituents of the essential oil of lavender, is not on the list of allergenic compounds pursuant to the EU Cosmetics Directive. Thus, it does not need to be declared on cosmetic products sold within the EU. Recent studies at the University of Gothenburg have shown that linalyl acetate can cause allergic eczema.
May 22, 2015 – “Eczema keeps me from doing things that other people enjoy all the time, like going to the beach, riding my bike, going for a walk, and enjoying being outside,” says 13-year-old eczema patient, Isaiah Dixon. But that didn’t stop Isaiah from testifying in March at a Food and Drug Administration (FDA) hearing in Silver Spring, MD, on behalf of the National Eczema Association.
May 7, 2015 – Researchers from St. Jude Children’s Research Hospital have identified a protein that offers a new focus for developing targeted therapies to tame severe inflammation. Targeting this protein has lead to a greater understanding on how mutations in a protein can lead to atopic dermatitis.